TGTX TG Therapeutics (TGTX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001001316
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
257
13F, latest reported quarter
What the filings say about TGTX
Insiders, 180 days
-$274.8K net sold
1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$274.8K
1 notice
TG Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, TG THERAPEUTICS, INC. insiders sold a net $274.8K of stock across 24 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Nov 11, 2024.
- The trade is 3.0% of the 168,640 shares held after it.
- No other insider sold within 30 days.
- 257 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Charney Laurence N sold about $274.8K of TGTX on Sep 10, 2026; 257 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Jun 13, 2025.
- The trade is 2.2% of the 223,816 shares held after it.
- No other insider sold within 30 days.
- 257 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Echelard Yann sold about $162.8K of TGTX on Nov 24, 2025; 257 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Nov 11, 2024.
- The trade is 22.2% of the 94,061 shares held after it.
- No other insider sold within 30 days.
- 257 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lonial Sagar sold about $672.3K of TGTX on Sep 11, 2025; 257 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Nov 5, 2024.
- The trade is 4.4% of the 228,816 shares held after it.
- No other insider sold within 30 days.
- 257 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Echelard Yann sold about $369.4K of TGTX on Jun 13, 2025; 257 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jan 3, 2025.
- The trade is 1.5% of the 660,611 shares held after it.
- No other insider sold within 30 days.
- 257 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO Power Sean A sold about $285.9K of TGTX on Jan 6, 2025; 257 funds added in the latest 13F quarter.24 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$274.8K over 180 days
-$274.8K over 90 days
more than 50% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
257 funds bought in last quarter
more than 93% of Pharma & Biotech
Revenue
+87.3% year over year
more than 83% of Pharma & Biotech
Margin
72.6% net margin
more than 96% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
21.9% of the float short (float per yahoo 2026-10-27) · 18.9 days to cover · settled 2026-10-15
more than 93% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch TGTX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+68.5%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TGTX: institutional holders (13F)
13F holdings, latest reported quarter
22,050,045 sh
$1.2B
7,963,266 sh
$437.5M
7,786,471 sh
$427.8M
6,149,403 sh
$337.8M
3,642,216 sh
$200.1M
Congress trades in TGTX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TGTX planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Charney Laurence N
Filed 2026-09-10
$274.8K
TGTX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
CapForce IBD Breakout Opportunities ETF
$602.0K position · as of 2026-07-31
3.7%
CapForce IBD 50 ETF
$2.8M position · as of 2026-07-31
3.5%
Congress Small Cap Growth Fund
$67.6M position · as of 2026-07-31
3.4%
Invesco S&P SmallCap Health Care ETF
$3.6M position · as of 2026-05-31
2.8%
Invesco S&P SmallCap Quality ETF
$5.3M position · as of 2026-05-31
2.3%
ClearBridge Variable Small Cap Growth Portfolio
$7.6M position · as of 2026-06-30
1.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
22 registered trials, 12 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
4
Phase 1
1 active
8
Phase 2
3 active
4
Phase 3
3 active
4
Not applicable
4 active
2
Multi-phase
1 active
What changed recently
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Mi
2026-09-25 · Recruiting → Active Not Recruiting
,
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Mr. Weiss
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$25.6M
$28.3M
$3.8M
-43%
+20%
2024
$18.8M
$91.7M
$2.3M
-42%
-9%
2023
$18.5M
$41.2M
$1.9M
-67%
-8%
2022
$10.4M
-$42.9M
$2.0M
-77%
-11%
2021
$42.7M
-$114.1M
$1.5M
-63%
-1%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $274.8K sold by insiders over 180 days, 257 funds added last quarter, $274.8K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
TGTX financials
Revenue growth
+87.3%
XBRL, annual
Net margin
72.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$799.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM TGTX
| FY Dec 2025 | $616.3M |
| FY Dec 2024 | $329.0M |
| FY Dec 2023 | $233.7M |
| FY Dec 2022 | $2.8M |
| FY Dec 2021 | $6.7M |
| Jun 2026 | $240.3M |
| Mar 2026 | $204.9M |
| Dec 2025 | $192.6M |
| Sep 2025 | $161.7M |
| Jun 2025 | $141.1M |
| Mar 2025 | $120.9M |
| Dec 2024 | $108.2M |
| Sep 2024 | $83.9M |
At each fiscal year end
Single quarter
Net margin, TTM
+55.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM TGTX
| FY Dec 2025 | +72.6% |
| FY Dec 2024 | +7.1% |
| FY Dec 2023 | +5.4% |
| FY Dec 2022 | -7,123% |
| FY Dec 2021 | -5,204% |
| Jun 2026 | +3.2% |
| Mar 2026 | +9.7% |
| Dec 2025 | +12.0% |
| Sep 2025 | +241.7% |
| Jun 2025 | +20.0% |
| Mar 2025 | +4.2% |
| Dec 2024 | +21.6% |
| Sep 2024 | +4.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$17.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM TGTX
| FY Dec 2025 | -$25.0M |
| FY Dec 2024 | -$40.6M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -$176.2M |
| FY Dec 2021 | -$296.0M |
| Jun 2026 | $39.0M |
| Mar 2026 | -$17.9M |
| Dec 2025 | $19.6M |
| Sep 2025 | -$23.2M |
| Jun 2025 | $7.4M |
| Mar 2025 | -$28.7M |
| Dec 2024 | -$25.7M |
| Sep 2024 | -$12.2M |
At each fiscal year end
Single quarter
Debt to equity
1.23x
long-term 2026-06-30 plus current 2023-09-30 (33 months older than the period end); equity 2026-06-30
Debt to equity TGTX
| FY Dec 2025 | 0.38x |
| FY Dec 2024 | 1.10x |
| FY Dec 2023 | 0.62x |
| FY Dec 2022 | 1.21x |
| FY Dec 2021 | 0.29x |
| Jun 2026 | 1.23x |
| Mar 2026 | 1.28x |
| Dec 2025 | 0.38x |
| Sep 2025 | 0.40x |
| Jun 2025 | 0.89x |
| Mar 2025 | 1.03x |
| Dec 2024 | 1.10x |
| Sep 2024 | 1.27x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.02x
TTM operating cash flow over long-term 2026-06-30 plus current 2023-09-30 (33 months older than the period end)
Cash flow to debt TGTX
| FY Dec 2025 | -0.10x |
| FY Dec 2024 | -0.17x |
| FY Dec 2023 | -0.31x |
| FY Dec 2022 | -2.48x |
| FY Dec 2021 | -4.36x |
| Jun 2026 | 0.02x |
| Mar 2026 | -0.02x |
| Dec 2025 | -0.10x |
| Sep 2025 | -0.29x |
| Jun 2025 | -0.24x |
| Mar 2025 | -0.25x |
| Dec 2024 | -0.17x |
| Sep 2024 | -0.12x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+100.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity TGTX
| FY Dec 2025 | +102.8% |
| FY Dec 2024 | +12.2% |
| FY Dec 2023 | +11.6% |
| FY Dec 2022 | -134.1% |
| FY Dec 2021 | -92.0% |
| Jun 2026 | +100.3% |
| Mar 2026 | +112.6% |
| Dec 2025 | +102.8% |
| Sep 2025 | +112.0% |
| Jun 2025 | +26.6% |
| Mar 2025 | +19.7% |
| Dec 2024 | +12.2% |
| Sep 2024 | -8.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+37.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets TGTX
| FY Dec 2025 | +54.5% |
| FY Dec 2024 | +5.2% |
| FY Dec 2023 | +4.9% |
| FY Dec 2022 | -69.2% |
| FY Dec 2021 | -69.3% |
| Jun 2026 | +37.7% |
| Mar 2026 | +42.3% |
| Dec 2025 | +54.5% |
| Sep 2025 | +55.6% |
| Jun 2025 | +11.0% |
| Mar 2025 | +7.6% |
| Dec 2024 | +5.2% |
| Sep 2024 | -3.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate -335%, not meaningful
Return on invested capital TGTX
| FY Dec 2025 | n/a |
| FY Dec 2024 | +12.8% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | +21.4% |
| Mar 2025 | +16.5% |
| Dec 2024 | +12.8% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+14.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed TGTX
| FY Dec 2025 | +17.7% |
| FY Dec 2024 | +11.0% |
| FY Dec 2023 | +9.9% |
| FY Dec 2022 | -96.0% |
| FY Dec 2021 | -80.9% |
| Jun 2026 | +14.3% |
| Mar 2026 | +16.3% |
| Dec 2025 | +17.7% |
| Sep 2025 | +15.5% |
| Jun 2025 | +20.9% |
| Mar 2025 | +15.5% |
| Dec 2024 | +11.0% |
| Sep 2024 | -0.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
20.52x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing TGTX
| FY Dec 2025 | 10.72x |
| FY Dec 2024 | 215.00x |
| FY Dec 2023 | 1,708.00x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 19.98x |
| Mar 2026 | 11.57x |
| Dec 2025 | 10.72x |
| Sep 2025 | 12.99x |
| Jun 2025 | 97.27x |
| Mar 2025 | 164.29x |
| Dec 2024 | 215.00x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$8.9B
market value at close 2026-10-27 on 2026-08-03 shares, plus long-term 2026-06-30 plus current 2023-09-30 (33 months older than the period end), minus cash 2026-06-30
Enterprise value TGTX
| FY Dec 2025 | $4.9B |
| FY Dec 2024 | $4.8B |
| FY Dec 2023 | $2.6B |
| FY Dec 2022 | $1.7B |
| FY Dec 2021 | $2.5B |
| Jun 2026 | $8.7B |
| Mar 2026 | $5.6B |
| Dec 2025 | $4.9B |
| Sep 2025 | $5.9B |
| Jun 2025 | $5.8B |
| Mar 2025 | $6.3B |
| Dec 2024 | $4.8B |
| Sep 2024 | $3.7B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+0.2%
TTM free cash flow over market value at close 2026-10-27
FCF yield TGTX
| FY Dec 2025 | -0.5% |
| FY Dec 2024 | -0.9% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -10.2% |
| FY Dec 2021 | -10.9% |
| Jun 2026 | +0.2% |
| Mar 2026 | -0.3% |
| Dec 2025 | -0.5% |
| Sep 2025 | -1.2% |
| Jun 2025 | -1.0% |
| Mar 2025 | -1.0% |
| Dec 2024 | -0.9% |
| Sep 2024 | -0.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.03x
P/E over trailing EPS growth of 643%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing TGTX
| FY Dec 2025 | 0.01x |
| FY Dec 2024 | 0.17x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.03x |
| Mar 2026 | 0.01x |
| Dec 2025 | 0.01x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | 18.07x |
| Dec 2024 | 0.17x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $616.3M | $329.0M | $233.7M | $2.8M |
| Operating income | $123.3M | $41.9M | $20.6M | -$218.3M |
| Net income | $447.2M | $23.4M | $12.7M | -$198.3M |
| EPS (diluted) | 2.77 | 0.15 | 0.09 | -1.65 |
| Operating cash flow | -$24.8M | -$40.5M | -$31.4M | -$176.2M |
| Cash | $79.1M | $179.9M | $92.9M | $102.3M |
| Long-term debt | $245.6M | $244.4M | $100.1M | $71.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
TGTX Stock Sonar score 6/7 axes
Find similar shapesCompareTGTX ranks highest on profitability (95th percentile) and institutional and government (93rd), and lowest on risk and compliance (12th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
TGTX filings, in plain words
Are TG Therapeutics insiders buying or selling TGTX?
In the 180 days to 2026-10-28, TG Therapeutics insiders were net sellers, a net $274.8K across purchases and sales reported on Form 4, by 1 seller.
Are there planned insider sales of TGTX?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $274.8K of stock; the latest, by Charney Laurence N, was filed 2026-09-10.
Read the full summary
In the 180 days to 2026-10-28, TG Therapeutics insiders were net sellers of TGTX, a net $274.8K across purchases and sales reported on Form 4 by 1 seller. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $274.8K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
